EOLS
Evolus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EOLS
Evolus, Inc.
A beauty company that provides medical aesthetic products in the US
520 Newport Center Dr., Suite 1200, Newport Beach, California 92660
--
Evolus, Inc., was incorporated in Delaware in November 2012. The company is a global performance beauty company that provides breakthrough products with a customer focus. The company's primary market is the cash-payment aesthetic market, which consists of medical products that consumers buy directly out of their own pockets.
Earnings Call
Q1/2025
Estimate EPS-0.14
Actual EPS-0.15
Estimate Revenue72.44M
Actual Revenue68.50M
Evolus Q1 2025: Navigating Contradictions in Market Growth, Pricing Strategies, and Consumer Preferences
May 07,2025 07:14
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.09
Actual EPS-0.27
Estimate Revenue82.04M
Actual Revenue69.40M
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment
Aug 13,2025 11:38
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EOLS has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.18, missing expectations. The chart below visualizes how EOLS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EOLS has released its 2025 Q3 earnings report, with revenue of 68.97M, reflecting a YoY change of 12.90%, and net profit of -15.74M, showing a YoY change of 17.91%. The Sankey diagram below clearly presents EOLS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
